4-aminopyridine has been researched along with Amyotrophic Lateral Sclerosis in 6 studies
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peikert, K | 1 |
| Naumann, M | 2 |
| Günther, R | 1 |
| Wegner, F | 2 |
| Hermann, A | 2 |
| Naujock, M | 1 |
| Stanslowsky, N | 1 |
| Bufler, S | 1 |
| Reinhardt, P | 1 |
| Sterneckert, J | 1 |
| Kefalakes, E | 1 |
| Kassebaum, C | 1 |
| Bursch, F | 1 |
| Lojewski, X | 1 |
| Storch, A | 1 |
| Frickenhaus, M | 1 |
| Boeckers, TM | 1 |
| Putz, S | 1 |
| Demestre, M | 1 |
| Liebau, S | 1 |
| Klingenstein, M | 1 |
| Ludolph, AC | 1 |
| Dengler, R | 1 |
| Kim, KS | 1 |
| Petri, S | 1 |
| Tovar-y-Romo, LB | 1 |
| Tapia, R | 1 |
| Aisen, ML | 2 |
| Sevilla, D | 2 |
| Gibson, G | 1 |
| Kutt, H | 1 |
| Blau, A | 1 |
| Edelstein, L | 2 |
| Hatch, J | 1 |
| Blass, J | 2 |
| Zona, C | 1 |
| Ferri, A | 1 |
| Gabbianelli, R | 1 |
| Mercuri, NB | 1 |
| Bernardi, G | 1 |
| Rotilio, G | 1 |
| Carri, MT | 1 |
1 trial available for 4-aminopyridine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
A double-blind placebo-controlled study of 3,4-diaminopyridine in amytrophic lateral sclerosis patients on a rehabilitation unit.
Topics: 4-Aminopyridine; Administration, Oral; Aged; Amifampridine; Amyotrophic Lateral Sclerosis; Cross-Ove | 1996 |
5 other studies available for 4-aminopyridine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Off-Label Treatment of 4 Amyotrophic Lateral Sclerosis Patients With 4-Aminopyridine.
Topics: 4-Aminopyridine; Adult; Aged; Amyotrophic Lateral Sclerosis; Female; Humans; Male; Off-Label Use; Qu | 2019 |
4-Aminopyridine Induced Activity Rescues Hypoexcitable Motor Neurons from Amyotrophic Lateral Sclerosis Patient-Derived Induced Pluripotent Stem Cells.
Topics: 4-Aminopyridine; Amyotrophic Lateral Sclerosis; Caspases; Cell Differentiation; Endoplasmic Reticulu | 2016 |
Cerebral neurons of transgenic ALS mice are vulnerable to glutamate release stimulation but not to increased extracellular glutamate due to transport blockade.
Topics: 4-Aminopyridine; Amyotrophic Lateral Sclerosis; Animals; Biological Transport; Dicarboxylic Acids; D | 2006 |
3,4-diaminopyridine as a treatment for amyotrophic lateral sclerosis.
Topics: 4-Aminopyridine; Affect; Aged; Amifampridine; Amyotrophic Lateral Sclerosis; Cognition; Female; Huma | 1995 |
Voltage-activated sodium currents in a cell line expressing a Cu,Zn superoxide dismutase typical of familial ALS.
Topics: 4-Aminopyridine; Amyotrophic Lateral Sclerosis; Cadmium; Calcium; Electric Stimulation; Humans; Ion | 1998 |